Extraction-Free COVID-19 RT-PCR Kit
COVID-19
CommercialActive
Key Facts
About Pharmozyme
Pharmozyme is a private, commercial-stage diagnostics company leveraging its proprietary enzyme purification technology to produce high-fidelity qPCR kits. Its product portfolio targets high-volume infectious disease testing markets with its UTI qPCR panel (PFlexU1), respiratory panels (PFlex R1/R2), and an extraction-free COVID-19 RT-PCR kit. The company differentiates itself by addressing reagent contamination—a known pain point in molecular diagnostics—to improve test accuracy and reliability for clinical and research labs. It operates under an ISO 13485:2016 quality management system, indicating a focus on regulated medical device manufacturing.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |